diplomsko delo
Povzetek
Zaviralci imunskih kontrolnih točk in celice CAR-T sta terapevtska pristopa, ki se lahko uporabljata za zdravljenje raka. Obe terapiji vplivata na delovanje limfocitov T, a imata popolnoma drugačen mehanizem delovanja. Na eni strani imamo celice T, modificirane s sintetičnim himernim antigenskim receptorjem (CAR), ki obstaja v petih različnih izvedbah. Na drugi strani pa imamo zaviralce imunskih kontrolnih točk, kjer se uporablja humanizirana monoklonska protitelesa. Celice CAR-T s himernim receptorjem same prepoznajo in vežejo antigene ter nato preko izločanja granzima in perforina, sinteze citokinov ali Fas/FasL poti uničijo rakave celice. Pri zaviralcih imunskih kontrolnih točk pa se protitelesa anti-CTLA-4 in anti-PD-1 vežejo na inhibitorne receptorje na celicah T in tako preprečijo interakcije receptorjev CTLA-4 in PD-1 z ligandi. S tem omogočijo vzpostavitev naravnih efektorskih funkcij in blažijo kronično utrujenost celic T, s tem pa tudi njihovo protirakavo delovanje. Tekom diplomske naloge bom najprej podrobneje predstavila receptorja CTLA-4 in PD-1 in njune zaviralce ter celice CAR-T, nato pa bom izpostavila še glavne razlike v mehanizmu delovanja med terapijama.
Ključne besede
Celice CAR-T;zaviralci imunskih kontrolnih točk;mehanizem delovanja;imunoterapija raka;receptor CAR;PD-1/PD-L1;CTLA-4;
Podatki
Jezik: |
Slovenski jezik |
Leto izida: |
2024 |
Tipologija: |
2.11 - Diplomsko delo |
Organizacija: |
UL BF - Biotehniška fakulteta |
Založnik: |
[N. Stražišar] |
UDK: |
606:616-006:616-097(043.2) |
COBISS: |
207417603
|
Št. ogledov: |
62 |
Št. prenosov: |
10 |
Ocena: |
0 (0 glasov) |
Metapodatki: |
|
Ostali podatki
Sekundarni jezik: |
Angleški jezik |
Sekundarni naslov: |
Comparison of the mechanism of action of CAR-T cells and immune checkpoint inhibitors |
Sekundarni povzetek: |
Checkpoint inhibitors and CAR-T cells are therapeutic approaches that can be used to treat cancer. Both therapies affect the function of T lymphocytes, but they have completely different mechanisms of action. On one hand, there are T cells modified with a synthetic chimeric antigen receptor (CAR), which exists in five different versions. On the other hand, there are checkpoint inhibitors, which use humanized monoclonal antibodies. CAR-T cells with the chimeric receptor independently recognize and bind to antigens, and then destroy cancer cells through the secretion of granzyme and perforin, cytokine synthesis, or the Fas/FasL pathway. With checkpoint inhibitors, anti-CTLA-4 and anti-PD-1 antibodies bind to inhibitory receptors on T cells and thus prevent the interactions of CTLA-4 and PD-1 receptors with ligands. This enables the establishment of natural effector functions and alleviates chronic T cell fatigue, thereby enhancing their anti-cancer activity. In my thesis, I will first provide a detailed overview of the CTLA-4 and PD-1 receptors and their inhibitors, as well as CAR-T cells, and then highlight the main differences in the mechanisms of action between the two therapies. |
Sekundarne ključne besede: |
CAR-T cells;immune checkpoint inhibitors;mechanism of action;cancer immunotherapy;CAR-T receptor;PD-1/PD-L1;CTLA-4; |
Vrsta dela (COBISS): |
Diplomsko delo/naloga |
Študijski program: |
0 |
Konec prepovedi (OpenAIRE): |
1970-01-01 |
Komentar na gradivo: |
Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije |
Strani: |
1 spletni vir (1 datoteka PDF (VIII, 19 str.)) |
ID: |
24956241 |